Evercore ISI Cuts Abbott Laboratories Price Target to $112, Maintains Outperform Rating

AnalystProduct / Tech
โดย TheFly·Read original
Summary · why it matters

Evercore ISI analyst Vijay Kumar reduced the firm's price target on Abbott Laboratories to $112 from $120 while maintaining an Outperform rating on the shares. The updated target was included in the firm's second-quarter outlook for the MedTech, Life Sciences Tools, and Diagnostics industries. Evercore ISI noted that sector conditions remain supported by relatively healthy procedure volumes and capital spending trends. Separately, Tandem Diabetes Care announced that its t:slim X2 insulin pump with Control-IQ+ technology is now compatible with Abbott's FreeStyle Libre 3 Plus continuous glucose monitoring sensor in five countries, with broader European availability expected in 2026.

Impact on stocks 3

Biotech & Genomic Medicine▲ · 2 stocks
Tandem Diabetes Care Inc
TNDM
▲ PositiveTechnologyrelevance

Tandem's t:slim X2 insulin pump is now compatible with Abbott's FreeStyle Libre 3 Plus CGM sensor in five countries, with broader European availability expected in 2026.

Abbott Laboratories
ABT
± MixedCapitalrelevance

Evercore ISI lowered price target to $112 but maintained Outperform rating; sector conditions supported by healthy procedure volumes and capital spending.

Financials▲ · 1 stocks
© 2026 MarketDXNews